Gilead Sciences, Inc. vs NetApp Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while NetApp Inc. trades at $199.84 (market cap $38.95B). The key difference: Gilead Sciences, Inc. is far larger — about 4.3× NetApp Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | NTAP | |
|---|---|---|
Market Cap | $168.35B | $38.95B |
Sector | Health | Technology |
52-Week High | $155.80 | $198.72 |
52-Week Low | $110.56 | $94.11 |
Enterprise Value | $191.42B | $38.10B |
Dividend Yield | 2.42% | 1.05% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →